<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        
        
        
        <link rel="shortcut icon" href="../../img/favicon.ico">
        <title>HMS leukemia and MDS - MediWiki</title>
        <link href="../../css/bootstrap.min.css" rel="stylesheet">
        <link href="../../css/font-awesome.min.css" rel="stylesheet">
        <link href="../../css/base.css" rel="stylesheet">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/color-brewer.min.css">
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
        <script>hljs.highlightAll();</script> 
    </head>

    <body>
        <div class="navbar fixed-top navbar-expand-lg navbar-dark bg-primary">
            <div class="container">
                <a class="navbar-brand" href="../..">MediWiki</a>
                <!-- Expander button -->
                <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#navbar-collapse">
                    <span class="navbar-toggler-icon"></span>
                </button>

                <!-- Expanded navigation -->
                <div id="navbar-collapse" class="navbar-collapse collapse">
                        <!-- Main navigation -->
                        <ul class="nav navbar-nav">
                            <li class="navitem">
                                <a href="../../Basic%20Clinical%20Sciences.html" class="nav-link">Basic Clinical Sciences</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Internal%20Medicine.html" class="nav-link">Internal Medicine</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Surgery.html" class="nav-link">Surgery</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Psychiatry.html" class="nav-link">Psychiatry</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Critical%20Care.html" class="nav-link">Critical Care</a>
                            </li>
                        </ul>

                    <ul class="nav navbar-nav ml-auto">
                        <li class="nav-item">
                            <a href="#" class="nav-link" data-toggle="modal" data-target="#mkdocs_search_modal">
                                <i class="fa fa-search"></i> Search
                            </a>
                        </li>
                            <li class="nav-item">
                                <a rel="prev" href="Graft%20vs%20Host%20Disease%20%28GvHD%29.html" class="nav-link">
                                    <i class="fa fa-arrow-left"></i> Previous
                                </a>
                            </li>
                            <li class="nav-item">
                                <a rel="next" href="Hereditary%20cancer%20syndromes.html" class="nav-link">
                                    Next <i class="fa fa-arrow-right"></i>
                                </a>
                            </li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="container">
            <div class="row">
                    <div class="col-md-3"><div class="navbar-light navbar-expand-md bs-sidebar hidden-print affix" role="complementary">
    <div class="navbar-header">
        <button type="button" class="navbar-toggler collapsed" data-toggle="collapse" data-target="#toc-collapse" title="Table of Contents">
            <span class="fa fa-angle-down"></span>
        </button>
    </div>

    
    <div id="toc-collapse" class="navbar-collapse collapse card bg-secondary">
        <ul class="nav flex-column">
            
            <li class="nav-item" data-level="2"><a href="#chronic-lymphocytic-leukemia" class="nav-link">Chronic lymphocytic leukemia</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            
            <li class="nav-item" data-level="2"><a href="#acute-lymphocytic-leukemia" class="nav-link">Acute lymphocytic leukemia</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            
            <li class="nav-item" data-level="1"><a href="#myelodysplastic-syndromes" class="nav-link">Myelodysplastic syndromes</a>
              <ul class="nav flex-column">
            <li class="nav-item" data-level="2"><a href="#aml" class="nav-link">AML</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#apml-m3" class="nav-link">APML-M3</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#cml" class="nav-link">CML</a>
              <ul class="nav flex-column">
              </ul>
            </li>
              </ul>
            </li>
        </ul>
    </div>
</div></div>
                    <div class="col-md-9" role="main">

<h2 id="chronic-lymphocytic-leukemia">Chronic lymphocytic leukemia</h2>
<ul>
<li>Epidemiology<ul>
<li>heterogenous</li>
<li>most common leukemia in western world</li>
<li>median age 65 (older)</li>
<li>BM, LN, spleen involvement at diagnosis</li>
<li>B-cell malignancy - CD19, CD20, CD5, CD23</li>
</ul>
</li>
<li>complications<ul>
<li>AIHA</li>
<li>hypogammaglobulinaemia</li>
<li>secondary malignancy risk (defective immune surveillance)</li>
</ul>
</li>
<li>Prognostic factors -IPI<ul>
<li>TP53 (17p) del/mutation → strong determinant; worse in mutations</li>
<li>IGHV (unmutated)</li>
<li>B2 microglobulin &gt; 3.5 </li>
<li>clinical stage - Binet B/C</li>
<li>Age &gt; 65</li>
</ul>
</li>
<li>Who and when to treat - IPI score<ul>
<li>low score → do not treat → 93% 5yr survival</li>
<li>intermediate (2-3) - no treat unless sx (79%)</li>
<li>high risk (4-6) → treat unless asx (63%)</li>
<li>very high esp tp53 (7-10) → novel inhibitor or clinical trial (23)</li>
<li>no increased survival with early CLL treatment</li>
</ul>
</li>
<li>Treatment options<ul>
<li>under 65 - ibrutinib PO<ul>
<li>FCR if healthy, brutixumab/rituxin reasinable alternative</li>
<li>del17p - treatment naive; iburitinb; role of allogenic stem cell transplant unclear</li>
<li>unmutated IGHV - consider ibrutib or FCR</li>
</ul>
</li>
<li>over 65<ul>
<li>high risk cytogenetics - ibrutinib</li>
<li>others: bendamustine/rutix; CLB + obinutuzumab, CLB + ofatumumab; ibrutinib</li>
</ul>
</li>
</ul>
</li>
<li>complications<ul>
<li>hypogammaglobulinaemia common<ul>
<li>encapsulated organism infection</li>
<li>consider IVIg replacement for recurrent infections - pneumonia, bronchitis, sinusitis</li>
</ul>
</li>
<li>progressive granulocytopenia - consider G-CSF</li>
<li>severe T-cell immunosuppression<ul>
<li>listeria, PCP infections</li>
<li>fludarabine reduces CD4+ T-cell counts</li>
<li>PCP prophylaxis need</li>
<li>cMV reactivation in alemtuzumab (not used as much now)</li>
<li>funal infections (e.g. cryptococcus) seen in ibrutinib treated patients - in first several months</li>
</ul>
</li>
<li>autoimmune complications<ul>
<li>AIHA - treat with steroids, IVIg - seen after fludarabine Tx</li>
<li>ITP - steroids, IVIg</li>
</ul>
</li>
<li>secondary malignancies - routine monitoring needed</li>
<li>risk of transformation to aggressive disease<ul>
<li>rapidly LN enlargement, LDH increase, B-symptoms</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Fludarabine
 - purine analogie
 - good response when combined; found in FCR (fludarabine, cyclophosphamide, rituxan)
 - SE
     - myelosuppression
     - TLS
     - hemolytic anaemia - unclear if related to treatment
     - opportunistic infecitons - due to T-cell suppression
         - shouldn't be combined with prednisone
         - need to given PCP prophylaxis</p>
<p>Ibrutinib - major agent
- BTK inhibitor
- oral administration
- lymphocyte counts rise when therapy initiated - do not discontinue if an initial rise is seen
- SE
    - myelosuppression
    - infections - esp fungal
    - atrial fibrillation (6%) - especially in older patients
    - bleeding (6%) - increased spontaneous bleed and post-op bleeding; particularly concerning for older patients
        - prior to MINOR surgery, hold for 3-5 days
        - for MAJOR surgery, hold for 7-10 days and a few days POST op
- Studies
    - increases overall/progression free surivavl in frontline CLL (when combared to chlorambucil)
        - 90% 18m PFS vs 52%
        - 24m OS -98% vs. 85% chlorambucil</p>
<p>Venetoclax
- upfront treatment of 17p abnormality CLL or second line after ibrutinib failure</p>
<h2 id="acute-lymphocytic-leukemia">Acute lymphocytic leukemia</h2>
<ul>
<li>Epidemiology<ul>
<li>most common childhood cancer, age 3-5 years, bimodal peak at 50</li>
<li>assoc w/ Down syndrome, Bloom's, Ataxia-telangiectasia</li>
<li>~ 15% of adult leukema</li>
</ul>
</li>
<li>Prognostication<ul>
<li>Age &gt;= 350-40</li>
<li>features - WCC &gt; 25000, ETP, T-ALL (genetic features)</li>
<li>cytogeneics - Ph+ (9, 22) or Ph-like (4;11) → seen in 25% of adults (&gt;40% pts over 60)</li>
<li>delayed response to induction - &gt; 4-6 weeks to get to remission</li>
<li>minimal residual disease - defined milestones </li>
</ul>
</li>
<li>Treatment<ul>
<li>induction - multiagent chemotherapy - e.g. cytoxan, adriamycin, L-aspariginase, vincristine, prednisone</li>
<li>consolidation - CNS prophylaxis (high relase risk), maintenance chemotherapy extends for ~ 2 years</li>
<li>Risk adapted therapy<ul>
<li>high risk patients (cytogeneic abnormalities), adverse features (MRD)<ul>
<li>should get treatment → allogeneic BMT in first remission</li>
</ul>
</li>
<li>standard risk<ul>
<li>chemotherapy alone + monitoring</li>
</ul>
</li>
<li>relapse after chemo<ul>
<li>salvage chemo → BMT, CAR-T cells</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Subclasses of ALL<ul>
<li>PH+ ALL<ul>
<li>25% adults, 40-60% of patients over 60</li>
<li>Diagnosis - FISH or cytogenetics; can be monitored with PCR</li>
<li>9;22 Bcr-Abl translocation; p190 transcript 70%, p210 in 30% (CML)</li>
<li>treatment - CTx + TKI<ul>
<li>TKI + steroids (i.e. no CTx) can be considered - italian data</li>
<li>Stem cell transplant if appropriate donor</li>
<li>PCR negative - TKI alone MAY be appropriate in younger adults</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Prognosis<ul>
<li>5-year leukemia free survival 30-55% </li>
</ul>
</li>
<li>Complications<ul>
<li>infections - prednisone increases infection risk e.g. PCP - consider PCP prophlaxis</li>
<li>avascular necrosis - related to prior steroid therapy, esp in younger</li>
<li>relapse sites - CNS and testicles are potential sites of relapse</li>
</ul>
</li>
</ul>
<p>CAR T-cells
- in ALL - attacks target/cosignalling domains
<img alt="" src="../../figures/Pasted%20image%2020231024145346.png" /></p>
<h1 id="myelodysplastic-syndromes">Myelodysplastic syndromes</h1>
<ul>
<li>stem cell disorder in older people</li>
<li>increased risk from previous ctx/rtx</li>
<li>cyotpenia on presentation</li>
</ul>
<p>BMB - hypercellular marrow (MORE), trilinear dysplasia - irregular nuclear formations and RBC precursors</p>
<ul>
<li>Differentials<ul>
<li>Anaemia of chronic disease</li>
<li>marrow infiltration</li>
<li>drug toxicity (EtOH, chemotherapy, INH)</li>
<li>Viral infections (HIV)</li>
<li>Vitamin deficiency (B12, folate)</li>
<li>MCV often elevated in MDS patients</li>
</ul>
</li>
<li>Prognostication - IPSS-R<ul>
<li>cytogenetics - TP53, EZH2, ETV6, RUNX1, ASXL1</li>
<li>marrow blas popualtion</li>
<li>anaemia(Hb)</li>
<li>ANC low</li>
<li>Plt low</li>
</ul>
</li>
<li>treatments - depends on age, performance, IPSS<ul>
<li>supprtive care - anaemia only<ul>
<li>chelation therapy for Fe overload</li>
</ul>
</li>
<li>RARS - may respond to pyridoxine</li>
<li>growth factors<ul>
<li>EPO (for EPO &lt; 500), anaemia mx</li>
<li>G-CSF but can drive leukemic progression</li>
</ul>
</li>
<li>CTx<ul>
<li>5-azacytidine (vs. conventional care, better overall survival)</li>
<li>lenalidomide (5q- syndrome)<ul>
<li>older women, anaemia and high plt, SF3B1 mutation - prolonged course</li>
</ul>
</li>
</ul>
</li>
<li>allogenic BMT is only curative treatment</li>
</ul>
</li>
</ul>
<h2 id="aml">AML</h2>
<ul>
<li>cindience 2.4/100000</li>
<li>median age 65-70; assocated with prior irradiation and toxin exposure<ul>
<li>may arise from previous MDS</li>
</ul>
</li>
<li>BM findings - large blasts, auer rods, visible nucleoli; CD13, CD33, CD11</li>
<li>cytogeneics<ul>
<li>favourable: t(8, 21), inv16 - AML1-core binding factor b<ul>
<li>t(15,17)</li>
</ul>
</li>
<li>adverse outcomes: -5, -7, 11q23, trisomy 8, 13, t(6;9)<ul>
<li>complex - &gt;=3 cytogenetics</li>
</ul>
</li>
<li>cytogenetics most important in prognosis</li>
</ul>
</li>
<li>key prognostic data<ul>
<li>age</li>
<li>cytogenetics</li>
<li>rpimary vs. secondary (?from previous MDS/chemortx)</li>
<li>molecular studies<ul>
<li>unfavourable: FLT3 ITD, KIT </li>
<li>favourabe: NPM1, CEBPA biallelic</li>
</ul>
</li>
</ul>
</li>
<li>treatment<ul>
<li>inducation - anthracycline, Ara-C - complete remission 6-80%, esp younger pts<ul>
<li>toxicity higher in older adults</li>
<li>lower intensity and recommended for older adults + p53 mutations (less chemo response anyway)</li>
</ul>
</li>
<li>consolidation tx - chemotx/BMT<ul>
<li>high dose ara-C most common</li>
<li>RCT no sng diff b/w consolidation ctx, allgenic BMT, autologous BMT</li>
</ul>
</li>
<li>risk adapted tx<ul>
<li>favourabe cytogenetics - chemotx alone</li>
<li>unfavourable cytogenetics - allogeneic BMT</li>
<li>intermediate risk - noraml cytogenetics - chemo OR BMT (but BMT favourited in Meta-Analysis)</li>
</ul>
</li>
</ul>
</li>
<li>complications<ul>
<li>hyperleukocytosis - high blast count - affected respiratory compromise and/or AMS<ul>
<li>medical emergency</li>
<li>Tx: IV hydration, rapid induction cTx, leukopheresis, radiation therapy</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="apml-m3">APML-M3</h2>
<ul>
<li>ATRA used to treat - improved complete remission, reduces DIC complications</li>
<li>arsenic trioxide to treat relapsed patients</li>
<li>ATRA+Arsenic associated with &gt;85% Complete remission (i.e. nonchemotherapeutic regimen)</li>
</ul>
<h2 id="cml">CML</h2>
<ul>
<li>myeloproliferative disease characterised by t(9;22)</li>
<li>med age 53, m=f, assoc w/ irradiation; med surv 5y</li>
<li>rpresentation<ul>
<li>50% asymptomatic; fatige, weight loss, abdo discomfort, easy brusiing</li>
<li>leukostasis, priapism, thrombosis are rare</li>
</ul>
</li>
<li>Ph+ chromosome =in 90%; 5% have variant; 5% pH negative</li>
<li>treatments<ul>
<li>TKI imatinib - BCR-ABl<ul>
<li>oral, w/ minimal side effects - nausea  (55), myalgia (49), edema (60), rash (32), diarrhoea (29)</li>
</ul>
</li>
<li>chronic phase / low risk /intedmediate<ul>
<li>imatinib or 2nd gen TKI (intermediate)</li>
<li>95% 5yr survival</li>
<li>clinical milestones defined by PCR log reduction</li>
<li>can potentially stop TKI in some - 50% will recur, but can just restart</li>
</ul>
</li>
<li>accelerated blast crisis<ul>
<li>evaluate for BMT</li>
<li>CTx + TKI for blast crisis for these</li>
</ul>
</li>
</ul>
</li>
</ul></div>
            </div>
        </div>

        <footer class="col-md-12">
            <hr>
                <p>Copyright &copy; 2021 Weber Liu</p>
            <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a>.</p>
        </footer>
        <script src="../../js/jquery-3.6.0.min.js"></script>
        <script src="../../js/bootstrap.min.js"></script>
        <script>
            var base_url = "../..",
                shortcuts = {"help": 191, "next": 78, "previous": 80, "search": 83};
        </script>
        <script src="../../js/base.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="../../search/main.js"></script>

        <div class="modal" id="mkdocs_search_modal" tabindex="-1" role="dialog" aria-labelledby="searchModalLabel" aria-hidden="true">
    <div class="modal-dialog modal-lg">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="searchModalLabel">Search</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
                <p>From here you can search these documents. Enter your search terms below.</p>
                <form>
                    <div class="form-group">
                        <input type="search" class="form-control" placeholder="Search..." id="mkdocs-search-query" title="Type search term here">
                    </div>
                </form>
                <div id="mkdocs-search-results" data-no-results-text="No results found"></div>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div><div class="modal" id="mkdocs_keyboard_modal" tabindex="-1" role="dialog" aria-labelledby="keyboardModalLabel" aria-hidden="true">
    <div class="modal-dialog">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="keyboardModalLabel">Keyboard Shortcuts</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
              <table class="table">
                <thead>
                  <tr>
                    <th style="width: 20%;">Keys</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="help shortcut"><kbd>?</kbd></td>
                    <td>Open this help</td>
                  </tr>
                  <tr>
                    <td class="next shortcut"><kbd>n</kbd></td>
                    <td>Next page</td>
                  </tr>
                  <tr>
                    <td class="prev shortcut"><kbd>p</kbd></td>
                    <td>Previous page</td>
                  </tr>
                  <tr>
                    <td class="search shortcut"><kbd>s</kbd></td>
                    <td>Search</td>
                  </tr>
                </tbody>
              </table>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div>

    </body>
</html>
